A groundbreaking $8.7 million award is set to revolutionize genetic diagnosis for lymphatic diseases, thanks to a team of researchers led by Columbia University Vagelos College of Physicians and Surgeons. The Advanced Research Projects Agency for Health (ARPA-H) has funded the project, which aims to develop genetic tests to expedite the diagnosis of patients born with lymphatic system defects. This initiative, known as the Comprehensive Lymphatic Anomaly Revealing and Understanding Genomics (CLARUM) project, is a collaborative effort involving multiple institutions.
The lymphatic system, often overlooked, plays a vital role in maintaining fluid balance and transporting essential substances throughout the body. Defects in this system can lead to severe health issues, including breathing difficulties and increased susceptibility to infections. Approximately one in every 3,500 babies is born with lymphatic defects, requiring immediate medical attention. Many of these individuals face a dire prognosis due to their inability to mount an immune response to infections.
The CLARUM project's primary goal is to create advanced genetic diagnostic tests that can identify congenital lymphatic diseases more accurately and widely. By addressing the challenge of limited access to genetic testing in rural areas, the project aims to ensure that more patients receive appropriate diagnoses and treatments. The team expects to uncover 15 or more new genetic mutations associated with lymphatic disease, significantly enhancing the predictive value of genetic testing.
Currently, only about 20-30% of patients with lymphatic anomalies caused by specific mutations benefit from targeted treatments. However, the identification of more genes through this research could improve treatment options for a larger patient population. The collaborative effort involves six academic medical centers, pooling their resources to analyze genetic data from 2,000 patients.
The project will develop two comprehensive genetic panels, one at Columbia and another at CHOP, to screen specimens obtained through standard clinical care. Collaborators from various institutions will contribute unique cases, and the Broad Institute will employ advanced genetic bioinformatic techniques to identify novel genes. Additionally, cell- and zebrafish-based models will be utilized to rapidly assess the significance of variants of uncertain significance (VUS).
One of the project's key focuses is the development of a method to detect mosaic mutations before birth, potentially preventing the use of ineffective therapies with side effects on fetuses with cystic lymphatic malformations. The team aims to create two genetic tests within two years, utilizing common specimens to detect lymphatic anomalies and screen for germline and mosaic mutations in 73 genes associated with primary lymphatic anomalies. This could significantly reduce the time required for genetic diagnosis, enabling faster access to FDA-approved therapies targeting mutated genes.
The CHOP and Columbia teams will work with their technology ventures to commercialize the genetic panels for widespread clinical use. This award from ARPA-H's LIGHT Program signifies a significant advancement in the field, offering hope for improved patient care and outcomes in the diagnosis and treatment of lymphatic diseases.
